[Advances of driver gene and targeted therapy of non-small cell lung cancer].
作者： Hongyang Wang , Yan Huang , Dan Zhang
DOI: 10.3779/J.ISSN.1009-3419.2014.10.07
关键词:
摘要: Lung cancer is the leading cause of cancer-related mortality in worldwide. The discovery drive gene makes tumor treatment no longer "one-size-fits-all". Targeted therapy to change present situation drugs become "bullet" with eyes, effect visible and bring a revolution lung cancer. diver targeted have became new cedule non-small cell (NSCLC). Society Clinical Oncology (ASCO) has showed 11 kinds genes. Here, we review functional structural characteristics driver mutations.
lungca.org 参考文章(27)
Siwei Zhang, Xiaonong Zou, Wanqing Chen, Estimation and projection of lung cancer incidence and mortality in China Chinese journal of lung cancer. ,vol. 13, pp. 488- 493 ,(2010) , 10.3779/J.ISSN.1009-3419.2010.05.20
Levi A. Garraway, Caroline Emery, Nikhil Wagle, MEK1 Mutation Conferring Resistance to RAF and MEK Inhibitors ,(2011)
She-Juan An, Zhi-Hong Chen, Jian Su, Xu-Chao Zhang, Wen-Zhao Zhong, Jin-Ji Yang, Qing Zhou, Xue-Ning Yang, Ling Huang, Ji-Lin Guan, Qiang Nie, Hong-Hong Yan, Tony S. Mok, Yi-Long Wu, Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status PLoS ONE. ,vol. 7, pp. e40109- ,(2012) , 10.1371/JOURNAL.PONE.0040109
Thanyanan Reungwetwattana, Saravut J. Weroha, Julian R. Molina, Oncogenic Pathways, Molecularly Targeted Therapies, and Highlighted Clinical Trials in Non–Small-Cell Lung Cancer (NSCLC) Clinical Lung Cancer. ,vol. 13, pp. 252- 266 ,(2012) , 10.1016/J.CLLC.2011.09.004
Susumu Kobayashi, Titus J. Boggon, Tajhal Dayaram, Pasi A. Jänne, Olivier Kocher, Matthew Meyerson, Bruce E. Johnson, Michael J. Eck, Daniel G. Tenen, Balázs Halmos, EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib The New England Journal of Medicine. ,vol. 352, pp. 786- 792 ,(2005) , 10.1056/NEJMOA044238
Timothy A. Yap, Li Yan, Amita Patnaik, Ivy Fearen, David Olmos, Kyriakos Papadopoulos, Richard D. Baird, Liliana Delgado, Adekemi Taylor, Lisa Lupinacci, Ruth Riisnaes, Lorna L. Pope, Simon P. Heaton, George Thomas, Michelle D. Garrett, Daniel M. Sullivan, Johann S. de Bono, Anthony W. Tolcher, First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors Journal of Clinical Oncology. ,vol. 29, pp. 4688- 4695 ,(2011) , 10.1200/JCO.2011.35.5263
Jianyong Chen, Cheng Jiang, Shaomeng Wang, LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor. Journal of Medicinal Chemistry. ,vol. 56, pp. 5673- 5674 ,(2013) , 10.1021/JM401005U
Maria Planck, Sofi Isaksson, Srinivas Veerla, Johan Staaf, None, Identification of Transcriptional Subgroups in EGFR-Mutated and EGFR/KRAS Wild-Type Lung Adenocarcinoma Reveals Gene Signatures Associated with Patient Outcome Clinical Cancer Research. ,vol. 19, pp. 5116- 5126 ,(2013) , 10.1158/1078-0432.CCR-13-0928
Robert C. Doebele, Amanda B. Pilling, Dara L. Aisner, Tatiana G. Kutateladze, Anh T. Le, Andrew J. Weickhardt, Kimi L. Kondo, Derek J. Linderman, Lynn E. Heasley, Wilbur A. Franklin, Marileila Varella-Garcia, D. Ross Camidge, Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer Clinical Cancer Research. ,vol. 18, pp. 1472- 1482 ,(2012) , 10.1158/1078-0432.CCR-11-2906
Eunice L. Kwak, Yung-Jue Bang, D. Ross Camidge, Alice T. Shaw, Benjamin Solomon, Robert G. Maki, Sai-Hong I. Ou, Bruce J. Dezube, Pasi A. Jänne, Daniel B. Costa, Marileila Varella-Garcia, Woo-Ho Kim, Thomas J. Lynch, Panos Fidias, Hannah Stubbs, Jeffrey A. Engelman, Lecia V. Sequist, WeiWei Tan, Leena Gandhi, Mari Mino-Kenudson, Greg C. Wei, S. Martin Shreeve, Mark J. Ratain, Jeffrey Settleman, James G. Christensen, Daniel A. Haber, Keith Wilner, Ravi Salgia, Geoffrey I. Shapiro, Jeffrey W. Clark, A. John Iafrate, Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer The New England Journal of Medicine. ,vol. 363, pp. 1693- 1703 ,(2010) , 10.1056/NEJMOA1006448